JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2023-08-03 ms1000001633014790 来自陕西省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵

225 35

展开35条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-03-12 ms6000001537745536 来自四川省

二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed

19 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-03-26 ms6000000287967542 来自浙江省

求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！

18 22

展开22条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-03-06 ms8000000280791103 来自重庆

偏重的研究方向：肿瘤基础研究
经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。

19 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-04-30 huahaha 来自广西

捉急的等待，不知道啥时候有结果。。。
Version 1 (private)
received 11 Mar, 2024

Reviews received
Received 24 Apr, 2024
Reviewers agreed
On 27 Mar, 2024
Reviewers invited
Invitations sent on 21 Mar, 2024
Submission checks complete
On 13 Mar, 2024
Editor assigned
On 13 Mar, 2024
First submitted to Journal of Cancer Research and Clinical Oncology
On 11 Mar, 2024

8 0

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-04-15 ms7000001719461797 来自重庆

偏重的研究方向：免疫;肿瘤;生信
经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊

13 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-04-07 ms6000001440282685 来自江苏省

记录一下，bulk+单细胞纯生信一篇
Submission under peer review 30 Mar 2024
Submission passed technical check 30 Mar 2024
Submission is under technical check 29 Mar 2024
Submission received 29 Mar 2024

15 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-01-19 ms3000000321226977

偏重的研究方向：肿瘤
经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见

65 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2024-04-15 ms7000001719461797 来自重庆

审稿速度:2.0
偏重的研究方向：免疫;肿瘤;生信
经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191574, encodeId=675421915e4a7, content=偏重的研究方向：肿瘤基础研究 经验分享：难受啊，2月13提交的，然后一直都是有一个人接受审稿，直到2月29号，系统出现问题，就没有更新了。然后今天3月6号发了个邮件给编辑询问进度，然后系统就变成了这样：The editors' decision can take several weeks as they may consult peer reviewers. 还没有修过，是不是要被拒了啊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:45:16 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=490, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2020-06-12 ms5502585941462392

9月28投稿，10月7日直接接收，还以为是拒稿。😀

490 125

展开125条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务